References

  1. French MA, Mallal SA, Dawkins RL. Zidovudine-induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients. AIDS 1992; 6:1293-7.
  2. French MA, Lenzo N, John M et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000; 1:107-15.
  3. French MA. Immune reconstitution inflammatory syndrome: immune restoration disease 20 years on. Med J Aust 2012; 196:318-21.
  4. Sun HY, Alexander BD, Huprikar S, et al. Predictors of immune reconstitution syndrome in organ transplant recipients with cryptococcosis: implications for the management of immunosuppression. Clin Infect Dis 2015; 60:36-44.
  5. Sun HY. Singh N. Opportunistic infection-associated immune reconstitution syndrome in transplant recipients. Clin Infect Dis 2011; 53:168-76
  6. Tan IL, McArthur JC, Clifford DB et al. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology. 2011; 77:1061-1067.
  7. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18:1615-27.
  8. Robertson J, Meier M, Wall J et al. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis. 2006; 42:1639-46.
  9. Haddow LJ, Easterbrook PJ, Mosam A et al. Defining Immune Reconstitution Inflammatory Syndrome: Evaluation of Expert Opinion versus 2 Case Definitions in a South African Cohort. Clin Infect Dis 2009; 9:1424-1432.
  10. Meintjes G, Lawn SD, Scano F et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008; 8:516-23.
  11. Haddow LJ, Colebunders R, Meintjes G, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis 2010; 10:791-802.
  12. Ruiz-Cruz M, Alvarado-de la Barrera C, Ablanedo-Terrazas Y et al. Clinical case definitions for cytomegalovirus-immune recovery retinitis. Clin Infect Dis. 2014; 59:298-303.
  13. French MA. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis 2009; 48:101-7.
  14. Yoon HA, Nakouzi A, Chang CC et al. Association between plasma antibody responses and risk for Cryptococcus-associated immune reconstitution inflammatory syndrome. J Infect Dis. 2019; 219:420-428.
  15. Ravimohan S, Tamuhla N, Nfanyana K et al. Robust Reconstitution of Tuberculosis-Specific Polyfunctional CD4+ T-Cell Responses and Rising Systemic Interleukin 6 in Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. Clin Infect Dis. 2016; 62:795-803.
  16. Hsu DC, Breglio KF, Pei L et al. Emergence of Polyfunctional Cytotoxic CD4+ T Cells in Mycobacterium avium Immune Reconstitution Inflammatory Syndrome in Human Immunodeficiency Virus-Infected Patients. Clin Infect Dis. 2018; 67:437-446.
  17. Chang CC, Lim A, Omarjee S, et al. Cryptococcosis-IRIS is associated with lower cryptococcus-specific IFN-gamma responses before antiretroviral therapy but not higher T-cell responses during therapy. J Infect Dis 2013; 208:898-906.
  18. Andrade BB, Singh A, Narendran G, et al. Mycobacterial antigen driven activation of CD14++CD16- monocytes is a predictor of tuberculosis-associated immune reconstitution inflammatory syndrome. PLoS Pathog 2014; 10:e1004433
  19. Tan HY, Yong YK, Andrade BB et al. Plasma interleukin-18 levels are a biomarker of innate immune responses that predict and characterize tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2015; 29:421-31.
  20. Tan HY, Yong YK, Shankar EM et al. Aberrant Inflammasome Activation Characterizes Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. J Immunol. 2016; 196:4052-63.
  21. Hsu DC, Breglio KF, Pei L et al. Emergence of Polyfunctional Cytotoxic CD4+ T Cells in Mycobacterium avium Immune Reconstitution Inflammatory Syndrome in Human Immunodeficiency Virus-Infected Patients. Clin Infect Dis. 2018; 67:437-446.
  22. Chang CC, Omarjee S, Lim A et al. Chemokine levels and chemokine receptor expression in the blood and the cerebrospinal fluid of HIV-infected patients with cryptococcal meningitis and cryptococcosis-associated immune reconstitution inflammatory syndrome. J Infect Dis. 2013; 208:1604-12.
  23. Vlasova-St Louis I, Chang CC et al. Transcriptomic Predictors of Paradoxical Cryptococcosis-Associated Immune Reconstitution Inflammatory Syndrome. Open Forum Infect Dis. 2018; 5:ofy157.
  24. Chang CC, Sheikh V, Sereti I, et al. Immune reconstitution disorders in patients with HIV infection: from pathogenesis to prevention and treatment. Curr HIV/AIDS Rep 2014; 11:223-32
  25. Chang CC, Crane M, Zhou J, et al. HIV and co-infections. Immunol Rev 2013; 254:114-42.
  26. Colebunders R, French MA. Immune reconstitution inflammatory syndrome in HIV/AIDS. Chapter 395 in: Goldman L, Schafer A (editors), Goldman's Cecil Medicine 25e, 2015, Saunders Elsevier, USA
  27. Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010; 24:2381-90.
  28. Fournier A, Martin-Blondel G, Lechapt-Zalcman E et al. Immune Reconstitution Inflammatory Syndrome Unmasking or Worsening AIDS-Related Progressive Multifocal Leukoencephalopathy: A Literature Review. Front Immunol. 2017; 8:577.
  29. Hsu DC, Faldetta KF, Pei L, et al. A Paradoxical Treatment for a Paradoxical Condition: Infliximab Use in Three Cases of Mycobacterial IRIS. Clin Infect Dis 2016; 62:258-261.
  30. Richaud C, Ghosn J, Amazzough K et al. Anti-tumor necrosis factor monoclonal antibody for steroid-dependent TB-IRIS in AIDS. AIDS 2015; 29:1117-9.
  31. Lwin N, Boyle M, Davis JS. Adalimumab for Corticosteroid and Infliximab-Resistant Immune Reconstitution Inflammatory Syndrome in the Setting of TB/HIV Coinfection. Open Forum Infectious Diseases 2018; 5:ofy027.
  32. Martin-Blondel G, Cuzin L, Delobel P, et al. Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome management? AIDS 2009; 23:2545-6.
  33. INSIGHT START Study Group. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med 2015; 373:795-807.
  34. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4:e5575.
  35. Sax PE, Sloan CE, Schackman BR, et al. Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164. HIV Clin Trials 2010; 11:248-59.
  36. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362:697-706.
  37. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365:1471-81.
  38. Havlir DV. Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365:1482-91.
  39. Uthman OA, Okwundu C, Gbenga K, et al. Optimal timing of antiretroviral therapy initiation for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis. Ann Intern Med 2015; 163:32-9.
  40. Török ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. Clin Infect Dis 2011; 52:1374-83.
  41. Bisson GP, Molefi M, Bellamy S, et al. Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis. Clin Infect Dis 2013; 56:1165-73.
  42. Boulware DR, Meya DB, Muzoora C, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med 2014; 370:2487-98
  43. Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis 2010; 50:1532-8.
  44. Psichogiou M, Basoulis D, Tsikala-Vafea M et al. Integrase Strand Transfer Inhibitors and the Emergence of Immune Reconstitution Inflammatory Syndrome (IRIS). Curr HIV Res. 2017; 15:405-410.
  45. Dutertre M, Cuzin L, Demonchy E et al. Initiation of Antiretroviral Therapy Containing Integrase Inhibitors Increases the Risk of IRIS Requiring Hospitalization. J Acquir Immune Defic Syndr. 2017; 76:e23-e26.
  46. Kityo C, Szubert AJ, Siika A et al. Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial. PLoS Med. 2018; 15:e1002706.
  47. Sierra-Madero JG, Ellenberg SS, Rassool MS, et al. Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial. Lancet HIV 2014; 1:e60-7.
  48. Meintjes G, Stek C, Blumenthal L et al. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. N Engl J Med. 2018; 379:1915-1925.
  49. Lebrun D, Hentzien M, Cuzin L et al. Epidemiology of autoimmune and inflammatory diseases in a French nationwide HIV cohort. AIDS 2017; 31:2159-2166.
  50. Sheikh V, Dersimonian R, Richterman AG, et al. Graves' disease as immune reconstitution disease in HIV-positive patients is associated with naive and primary thymic emigrant CD4(+) T-cell recovery. AIDS 2014; 28:31-9